Profiel
Karsten Meisloch has worked as a Co-Managing Director at Shire Orphan Therapies GmbH and Shire Deutschland GmbH.
Actieve functies van Karsten Meisloch
| Bedrijven | Functie | Begin |
|---|---|---|
Shire Deutschland GmbH
 Shire Deutschland GmbH Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Shire Deutschland GmbH develops therapies for patients with rare and other specific diseases. The private company is based in Berlin, Germany. The CEOs are Uwe Fröhlich, Heidrun Irschik-Hadjieff, Karsten Meisloch. The German company was founded in 1986. | Chief Executive Officer | - |
Shire Orphan Therapies GmbH
 Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | Chief Executive Officer | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Shire Orphan Therapies GmbH
Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | Health Technology |
Shire Deutschland GmbH
Shire Deutschland GmbH Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Shire Deutschland GmbH develops therapies for patients with rare and other specific diseases. The private company is based in Berlin, Germany. The CEOs are Uwe Fröhlich, Heidrun Irschik-Hadjieff, Karsten Meisloch. The German company was founded in 1986. | Health Technology |
